JBJ-09-063
allosteric mutant-EGFR inhibitor in vivo efficacy in osimertinib-resistant xenograft models from opt. of prev. disclosed EGFR inhibitor Nat. Cancer Dana-Farber Cancer Institute, Boston, MA
Molecules of the Month - April 2022
allosteric mutant-EGFR inhibitor in vivo efficacy in osimertinib-resistant xenograft models from opt. of prev. disclosed EGFR inhibitor Nat. Cancer Dana-Farber Cancer Institute, Boston, MA
Molecules of the Month - April 2022